2026-01-20 - Analysis Report
**Financial Report for Johnson & Johnson (JNJ)**

**Company Overview**
Johnson & Johnson is a multinational healthcare company that develops and markets healthcare products, including pharmaceuticals, medical devices, and consumer goods.

**Return Rate Comparison**

* Ticker: JNJ
* Cumulative return: 60.63%
* Cumulative return of comparison stock (S&P 500, VOO): 93.30%
* Divergence: -32.70 (-13.70 to -62.40)
* Relative divergence: 39.00% (0% to 100%)

The cumulative return of JNJ is lower than the comparison stock, indicating a decrease in its relative value.

**Alpha, Beta Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 6.0% | 16.8% | 2.0% | 0.7 | 310.9B |
| 2017-2019  | 18.0% | 16.8% | 1.0% | 0.7 | 351.4B |
| 2018-2020  | 19.0% | 16.8% | -2.0% | 0.7 | 379.2B |
| 2019-2021  | 32.0% | 10.7% | -12.0% | 0.6 | 412.2B |
| 2020-2022  | 8.0% | 13.8% | 10.0% | 0.5 | 425.6B |
| 2021-2023  | -18.0% | 13.8% | -19.0% | 0.3 | 377.6B |
| 2022-2024  | -30.0% | 13.8% | -49.0% | 0.2 | 348.4B |
| 2023-2025  | 30.0% | 13.8% | -32.0% | 0.1 | 498.6B |

The CAGR (Compound Annual Growth Rate) varies across different periods, indicating changing market conditions. The beta value is relatively stable, indicating consistent volatility.

**Recent Stock Price Fluctuations**

* 5-day SMA: $216.03
* 20-day SMA: $208.94
* 60-day SMA: $201.95
* Recent market data:
	+ Close: $218.66
	+ Last-market: {'previousClose': 219.57, 'change': -0.41}

The short-term moving averages are lower than the current price, indicating a potential short-term trend reversal.

**RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence**

* Market Risk Indicator (MRI): 0.80 (Risk Level: Medium)
* RSI: 70.76
* PPO: 0.54
* Hybrid Signal: Buy (Cash 0%)
* Recent (20 days) relative divergence change: 14.60 (+)
* 7-day Rank change: 64 (+)
* 7-day Dynamic Expected Return change: 9.80 (+)

The RSI and PPO indices are relatively high, indicating potential overextension. The MRI indicates a medium risk level, and the hybrid signal suggests a Buy rating.

**Expected Return**
-38.60%

The expected return is negative, indicating a potential loss in the long-term.

**Recent News & Significant Events**

Several recent news articles are relevant to the company:

1. Is Johnson & Johnson A Dividend Stock, Or Something Else? (NYSE:JNJ) - Seeking Alpha
2. Looking for Exposure to Johnson & Johnson Stock (JNJ) ahead of Q4 Earnings? Hereâ€™s How to Buy Without the Risk - TipRanks
3. Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results? - TradingView
4. Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
5. Johnson & Johnson $JNJ Shares Acquired by Focused Investors LLC - MarketBeat
6. More Upside For JNJ Stock In 2026? - Forbes

**Analyst Opinions**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.16 (~Buy)
- Opinions: 24
- Target Price (avg/high/low): 212.00 / 240.00 / 155.00

The analyst consensus is Buy, with a mean rating of 2.16.

**Recent Earnings Analysis**

| Date | EPS | Revenue |
|-----|----|--------|
| 2025-10-22 | 2.14 | $23.99B |
| 2025-07-24 | 2.3 | $23.74B |
| 2025-04-23 | 4.57 | $21.89B |
| 2024-10-23 | 1.12 | $22.47B |
| 2025-10-22 | 1.12 | $22.47B |

The EPS (Earnings Per Share) varies across different periods, indicating changing profitability. The revenue is stable, indicating consistent growth.

**Financial Information**

**Revenue and Profitability**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $23.99B | 69.56% |
| 2025-06-30 | $23.74B | 67.87% |
| 2025-03-31 | $21.89B | 66.40% |
| 2024-12-31 | $22.52B | 68.35% |
| 2024-09-30 | $22.47B | 69.01% |

The revenue is generally stable, with a slight increase in the last quarter. The profit margin varies across different quarters.

**Capital and Profitability**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $79.28B | 6.50% |
| 2025-06-30 | $78.47B | 7.06% |
| 2025-03-31 | $78.11B | 14.08% |
| 2024-12-31 | $71.49B | 4.80% |
| 2024-09-30 | $70.16B | 3.84% |

The equity is increasing, indicating growth in the company's capital. The ROE (Return on Equity) varies across different quarters.

**Comprehensive Analysis (Summary of previous items)**

Based on the analysis, JNJ has a relatively stable revenue and increasing equity, but its profitability and return on equity (ROE) vary across different quarters. The analysts' consensus is Buy, with a target price of $212.00. The market risk indicator suggests a medium risk level, and the RSI and PPO indices indicate potential overextension. However, the hybrid signal suggests a Buy rating, and the expected return is negative. Overall, JNJ is a stable company with a relatively low return on equity, but the recent short-term trend reversal and potential overextension suggest caution when investing in the company.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.